|
Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC). |
|
|
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech |
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; PharmaMar; Roche/Genentech; Taiho Pharmaceutical |
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech |
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst) |
Other Relationship - Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - DAEHWA Pharmaceutical; ISU ABXIS |
Consulting or Advisory Role - AstraZeneca; DAEHWA Pharmaceutical; ISU Abxis; Lilly (Inst) |
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst) |
|
|
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Lilly; MSD; Novartis; Pfizer/EMD Serono; Regeneron; Roche |
Travel, Accommodations, Expenses - Bristol Myers Squibb |
|
|
Honoraria - Abbvie; AstraZeneca; Lilly; Novartis; Roche |
Consulting or Advisory Role - Lilly; Novartis; Roche |
Speakers' Bureau - AstraZeneca; Lilly; Novartis; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Lilly; MSD; Novartis; Seagen |
Research Funding - AstraZeneca (Inst) |
Travel, Accommodations, Expenses - Novartis; Roche |
|
|
|
Consulting or Advisory Role - GlaxoSmithKline; MSD; Novartis |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Karyopharm Therapeutics |
Speakers' Bureau - Eisai; Janssen Oncology |
Research Funding - Sarah Cannon Research Institute (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Lilly; Lilly; MSD Oncology |
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Pfizer; United Medical |
|
|
Honoraria - AstraZeneca; Asuka Seiyaku; Chugai Pharma; Kyowa Hakko Kirin; Mochida Pharmaceutical Co. Ltd.; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - AstraZeneca |
|
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Lilly |
|
|
|
Stock and Other Ownership Interests - Amgen; AstraZeneca; Bayer; Chugai Pharma; Evgen; Johnson & Johnson; Lilly; Merck; Novartis; Pfizer; Roche; Takeda; Utah Medical Products; Varex Imaging; Varian Medical Systems; Zimmer BioMet; Zoetis |
|
|
Honoraria - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Puma Biotechnology |
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst) |
Expert Testimony - Novartis |